SYMPOSIUM

PRAGUE
22-24 MAY 2025

EADV Symposium scientific programme

The EADV Scientific Programming Committee has prepared a captivating and inspiring 3-day agenda that caters to the expectations of both young dermatologists-venereologists and seasoned professionals.

The specially curated programme promises an intimate experience with renowned speakers across 28 sessions

Session types

Sessions of different formats will cover the most important topics in dermatology and venereology. Subjects will be treated with different approaches and from different perspectives depending on the type and structure of the session.

The Plenary lectures are EADV show-case sessions and include key-note lectures delivered by eminent scientists and doctors.

These sessions will enable participants to update their knowledge on a specific topic and hear about the most relevant and recent developments, guidelines and practical knowledge from the past year. The talks will summarize the current understanding of the subject, followed by an update on the most recent novelties with their impact on clinical practice.

These sessions aim at providing comprehensive in-depth coverage of a certain topic in dermatology. The talks will be included in sessions on pathophysiology / epidemiology, clinical challenges, or practical aspects of disease management and will provide the latest cutting-edge information.

These lectures focus on a specific disease and include basic information about epidemiology, pathophysiology, diagnosis, management and prognosis. 

The target audience of these sessions is young dermatology trainees and residents, as well as dermatologists that want to refresh their basic knowledge on specific topics. 

The topic of each presentation should be developed from clinical cases and include clinical photographs. The main objective is to provide the audience clues for differential diagnosis and disease management in their daily practice. 

Each presentation is supposed to be interactive, with multiple-choice question made to the audience in accordance with the subjects treated in the talks. Each speaker will be asked to include 2-3 questions by “data” along with the different answers’ options.

Authors of the most highly-ranked abstracts assessed by a selected panel of abstract reviewers are invited to a provide a 10-minute oral presentation.

Programme at a glance

Thursday, 22 May 2025

14:00 - 15:30

Melanoma

New targeted treatment:
Inflammatory diseases

Free communications 1

15:45 - 17:15

Keratinocytic skin cancer

New targeted treatment:
Inflammatory diseases

Free communications 2

17:30 - 18:30

Plenary session

Friday, 23 May 2025

09:00 - 10:30

Adverse anti-cancer drug reactions

Dermoscopy

New targeted treatment:
Inflammatory diseases

10:45 - 12:15

Hidradenitis suppurativa

Clinical-pathological correlations

New targeted treatment: Skin cancer

12:45 - 13:45

Industry sessions

14:00 - 15:30

Emergencies in dermatology

Hair and nail disorders

Viral infections:
Emerging threats

15:45 - 17:15

Regenerative medicine and aesthetics

Residents quiz the faculty

Viral infections:
Viruses and cancer

Saturday, 24 May 2025

09:00 - 10:30

Hair and Nails

Psoriasis

Viral infections:
Viruses and exanthema

10:45 - 12:15

Aesthetic dermatology

Genodermatoses

Viral infections:
Viruses and drugs

12:30 - 14:00

Paediatric dermatology

Joint EADV-IUSTI-EU Session on Venereology

Connective tissue diseases

Sessions spotlights

Hair and nail disorders

Interactive clinical cases

Scarring alopecia
Matilde Iorizzo, Switzerland

Scarring alopecia is a disease that is sometimes difficult to diagnose and treat. Cases of scarring alopecia in adult patients, from diagnosis to treatment, will be presented to give the audience insights on how to manage these difficult patients.

Learning objectives

  • Identify and differentiate subtypes of scarring alopecia
  • Interpret trichoscopy results
  • Develop tailored management plans

Non-scarring alopecia
Anastasia Therianou, United Kingdom

This is an interactive session where interesting cases of non- scarring alopecias are going to be presented.

Non-scarring alopecias such as female pattern hair loss, telogen effluvium or alopecia areata and many more, are very common in everyday clinical practice, however sometimes it is hard to make the diagnosis and arrange a management plan.

Through the presentation of 5-7 clinical cases (with medical history, clinical and dermoscopical images), the audience will be able to learn on how to successfully diagnose different types of non-scarring alopecia and how to successfully manage them.

Learning objectives

  • Learn how to diagnose and manage some interesting non-scarring alopecia cases

Hair and nail disorders in systemic diseases
Alexander Katoulis, Greece

Skin, including hair and nails, are rightly described as “windows” to systemic diseases, as they frequently display visible clues reflecting underlying conditions. This clinical case-based presentation explores the diagnostic significance of hair and nail manifestations in systemic disorders, highlighting the diagnostic and therapeutic complexities.

Systemic or auto-inflammatory diseases may affect also the scalp, causing secondary scarring alopecia, providing insights for the primary disease diagnosis and treatment. Especially hair involvement (non-scarring alopecia, lupus hair and chronic telogen effluvium) plays an important diagnostic role in systemic lupus erythematosus (SLE), representing one of the diagnostic criteria for SLE.

Internal cancer may manifest itself in multiple ways through hair: skin metastases from breast or lung cancer may appear as patches of alopecia; acquired hair disorders, such as hypertrichosis lanuginosa, represent paraneoplastic syndromes serving as markers of internal malignancy; chemotherapy-induced alopecia is the most distressing adverse reaction of cytotoxic chemotherapy; modern immunotherapy and targeted therapies for advanced neoplasms are not uncommonly associated with autoimmune hair disorders; and secondary scarring alopecia may develop at the sites of radiotherapy treatment.
Nail abnormalities, including changes in shape, texture, and color, often reflect systemic pathologies. Systemic illnesses, such as cardiovascular diseases, may cause splinter hemorrhages, while clubbing can signal chronic pulmonary disorders. Yellow nail syndrome is associated with lymphedema and respiratory conditions, and koilonychia may indicate iron deficiency anemia. Terry’s white nails are commonly linked to liver cirrhosis, congestive heart failure, or diabetes. Beau’s transverse lines of the nail plate, often reflect periods of systemic stress, such as severe illness or malnutrition.

Hair and nail manifestations provide vital diagnostic and prognostic insights into systemic diseases. Recognizing these signs can facilitate early diagnosis and tailored management of conditions like lupus and cancer. Future directions in this domain include the development of targeted therapies to mitigate treatment-induced hair and nail changes and the integration of trichoscopy and dermoscopy into routine clinical practice. Clinicians equipped with the tools to identify and manage hair and nail manifestations in systemic diseases can foster a multidisciplinary approach to patient care.

Learning objectives

  • Identify visible signs of systemic diseases in hair and nails
  • Recognize the diagnostic value of hair and nail abnormalities in systemic conditions
  • Assess the diagnostic importance of observing hair and nail changes during clinical evaluations
  • Integrate observations of hair and nail changes into holistic patient evaluations

Dystrophic nails
Marcel Pasch, Netherlands

Disease management for patients with dystrophic nails can be bothersome and sometimes frustrating in daily practice. To an untrained eye, many nail dystrophies look alike but successful treatment depends first and foremost on a correct diagnosis. 
Numerous causes can be responsible for disruption of normal nail growth, with infectious (onychomycosis), inflammatory (lichen planus, psoriasis, alopecia areata), traumatic (onychotillomania) and oncologic (melanoma, squamous cell carcinoma) being the most frequent. Participants in this session will be taken through history taking, investigations, diagnosis and management in an interactive manner with interactive polls. 
Through clinical cases with detailed clinical photographs, tools will be provided that will make the correct diagnosis and effective treatment of patients with nail dystrophy much easier than generally thought. In a number of patients, we will also discuss pitfalls that you do not want to miss and may serve as red flags that require immediate action.

Learning objectives

  • Successful treatment of nail dystrophy depends on a correct diagnosis.
  • The most frequent causes for nail dystrophy are infectious (onychomycosis), inflammatory (lichen planus, psoriasis, alopecia areata), traumatic (onychotillomania) and oncologic (melanoma, squamous cell carcinoma).
  • Making the correct diagnosis and effective treatment of patients with nail dystrophy is easier than generally thought.
  • Some clinical signs in nail dystrophy can serve as red flags requiring prompt action.

Dermoscopy

Interactive clinical cases

Pink/Red
Caterina Longo, Italy

Blue/Violet
Pedro Zaballos, Spain

Yellow/Orange
Ofer Reiter Agar , Israel

This session focuses on the use the color as a clue for clinical and dermoscopic diagnosis. The presentation will cover tumors where yellow (keratin and lipids; tumors with sebaceous differentiation, juvenile xanthogranuloma, granular tumors, sarcoidosis) and orange color (granulomatous skin diseases) are key findings.

Learning objective

  • Learn the differential diagnosis of skin tumors presenting yellow and orange color

Brown/Black
Monika Arenbergerova, Czechia

The colors are fundamental in dermoscopic evaluation. Most of the colors present on the skin originate from an increase of a specific chromophore in skin tissue, such as pigment (brown, black, gray, blue), keratin (yellow), collagen (white), or haemoglobin (red, black). The most important chromophore in pigmented lesions is melanin. Black coloring in dermoscopy appears when melanin is present in the stratum corneum or the upper epidermis; brown coloring appears when melanin is located in the mid or low epidermis. Black coloring revealed by dermoscopy does not always imply ominous conditions. Lesions which are black in dermoscopy can be of benign as well as malignant origin. Black coloring appears in melanocytic naevus (especially Reed naevus), seborrheic keratosis, thrombosed haemangioma, subcorneal haematoma, but also in melanoma and heavily pigmented basal cell carcinoma. The presentation will cover theoretical but also practical knowledge on dermoscopy of brown and black lesions.

Learning objectives

  • Identify and differentiate black and brown colors in dermoscopy to distinguish between malignant and benign lesions.

Stay informed with the latest advancements and expert insights from EADV

Letter from the Chair of the EADV Scientific Programming Committee

Dear Colleagues,

Prof. Michel Gilliet
Chair of the SPC

Michel Gilliet EADV

Scientific Programming Committee: Michel Gilliet (Chair of the SPC),  Jo Lambert, Paola Pasquali, Lidia Rudnicka, Eli Sprecher, Thrasyvoulos Tzellos

If you have any further questions about the Scientific Programme, Abstracts, CME Accreditation, or Certificates, please contact us at [email protected]

COMING SOON

HEALTHCARE PROFESSIONAL DEFINITION

Carefully read the description below to ensure you/your delegates comply with the country’s regulations.

EADV Members are not designated as Healthcare Professionals by default

Please, define the correct status (HCP or Non-HCP) during the registration process.

Definition

According to the European Union Directive 2001/83 /EC (and amended version 2010/84/EU), the promotion of prescription only medicines should be directed solely at Healthcare Professionals or any person who is authorised to prescribe or handle them.

As a multidisciplinary audience will be attending the EADV Symposium, the delegates must  indicate if they are Healthcare Professionals (HCP) or Non-Healthcare Professionals (Non-HCP) to ensure compliance with these regulations.

Access to the different areas and sessions of the Symposium depends on the status as Healthcare Professional or as Non-Healthcare Professional. 

The Pharmaceutical Research Based Industry Malta Association (2014) defines HCP as:

Any member of the medical, dental, pharmacy or nursing professions or any other person who in the course of his or her professional activities may prescribe, purchase, supply or administer a medicinal product. “

Industry sessions and advertising

Sections of the code also relevant to a congress held in Malta:

Any such promotional material (excluding promotional aids) is accompanied by a suitable statement indicating countries in which the product is registered and makes clear that the product or use is not registered locally, and any such promotional material which refers to the prescribing information (indications, warnings etc.) authorized in a country or countries where the medicinal product is registered should be accompanied by an explanatory statement indicating that registration conditions differ internationally.

Satellite Symposia presenting data on the development, research or other issues related to prescription medicine can be restricted to Healthcare Professionals and Industry Participants only upon indication provided by the Industry Session Organizer. All promotional materials and marketing aids related to these industry sessions should be strictly limited to HCPs only.

Industry Session organisers could limit participation to certain representative groups independently from the EADV recommendations if deemed imperative to the achievement of the intended purpose of the Industry session. The organising company reserves the right to refuse single categories, in particular if not adequately related to the objective and purpose of the session.

The industry session organizer is responsible for the compliance of the session.

Other categories

STUDENTS are NOT considered as Healthcare Professionals under the current guidelines and will be automatically classified as NON-HEALTHCARE PROFESSIONALS.

PATIENT ASSOCIATION REPRESENTATIVES must indicate whether they are Healthcare Professionals or not at registration.